Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor κB activation

Journal of General Virology

Volumn 91, Issue 9, 2010, Pages 2216-2220

  McCoy, Laura E ^a,b   Fahy, Aodhnait S ^a,c   Chen, Ron A J ^a,d   Smith, Geoffrey L ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; CYTOKINE; FIREFLY LUCIFERASE; I KAPPA B; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN 183; PROTEIN B14; PROTEIN BCL 2; RENILLA LUCIFERIN 2 MONOOXYGENASE; THREONINE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALINE; VIRULENCE FACTOR;

ALPHA HELIX; ARTICLE; B CELL LYMPHOMA; CELL LINE; CELL LYSATE; CRYSTAL STRUCTURE; CYTOMEGALOVIRUS; CYTOPLASM; ESCHERICHIA COLI; EUKARYOTIC CELL; FEMALE; GENE DELETION; GENE MUTATION; IMMUNOBLOTTING; IMMUNOGENICITY; INFLAMMATION; LEUKOCYTE; MODIFIED VIRUS ANKARA; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; VACCINIA VIRUS; VIRULENCE; VIRUS GENE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; GENES, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; NF-KAPPA B; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES; VIRULENCE;

EUKARYOTA; VACCINIA VIRUS;

EID: 77956287597     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.022343-0     Document Type: Article

References (26)

1. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396. (Pubitemid 28384101)
2. Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159-1167.
3. Chen, R. A., Jacobs, N. & Smith, G. L. (2006). Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol 87, 1451-1458. (Pubitemid 43827199)
4. Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. (2008). Inhibition of IκB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4, e22.
5. Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87, 29-38.
6. Falkner, F. G. & Moss, B. (1990). Transient dominant selection of recombinant vaccinia viruses. J Virol 64, 3108-3111.
7. Fenner, F., Anderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and its Eradication. Geneva: World Health Organization.
8. Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. M., Abrescia, N. G., Alderton, D., Owens, R. J., Stuart, D. I. & other authors (2008). Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-κB rather than apoptosis. PLoS Pathog 4, e1000128.
9. Hashizume, S., Yoshizawa, H., Morita, M. & Suzuki, K. (1985). Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In Vaccinia Viruses as Vectors for Vaccine Antigens, pp. 87-99. Edited by G. V. Quinnan. New York: Elsevier Science.
10. Hughes, S. J., Johnston, L. H., de Carlos, A. & Smith, G. L. (1991). Vaccinia virus encodes an active thymidylate kinase that complements a cdc8 mutant of Saccharomyces cerevisiae. J Biol Chem 266, 20103-20109.
11. Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969). Complications of smallpox vaccination, 1968. National surveillance in the United States. N Engl J Med 281, 1201-1208.
12. Mahnel, H. & Mayr, A. (1994). Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berl Munch Tierarztl Wochenschr 107, 253-256 (in German).
13. Mayr, A. & Munz, E. (1964). Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl Bakteriol Orig 195, 24-35 (in German).
14. Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. (1978). The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol [B] 167, 375-390 (in German).
15. Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., Howley, P., Chaplin, P. & other authors (2007). Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol 88, 3249-3259.
16. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038.
17. Moss, B. (2007). Poxviridae: the viruses and their replicaton. In Fields Virology, 5th edn, pp. 2905-2946. Edited by D. M. Knipe & P. M. Howley. Philadelphia, PA: Lippincott Williams & Wilkins.
18. Oie, K. L. & Pickup, D. J. (2001). Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-κB activation. Virology 288, 175-187.
19. r 43-50 K protein on the surface of extracellular enveloped virus. Virology 204, 376-390.
20. Satheshkumar, P. S., Anton, L. C., Sanz, P. & Moss, B. (2009). Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol 83, 2469-2479.
21. Smith, G. L., Mackett, M. & Moss, B. (1983). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490-495. (Pubitemid 13111130)
22. + T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 86, 1997-2006.
23. Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H. C., Schafer, H. & Holzner, A. (1974). MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch Med Wochenschr 99, 2386-2392 (in German).
24. Sutter, G. & Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89, 10847-10851.
25. Tscharke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80, 2751-2755.
26. Tscharke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83, 1977-1986.